This is how the Install App dialog will look like once your App goes live.
CONTENTSAutumn/ Winter 2021 New Methods in Drug Development 6 Vaccine Technology, Inspired by PlantsWhen millions of vaccines are needed around the world, manufacturers set to work to find the quickest and most effective way to produce them. New plant-based innovations could alter the path for future vaccines forever.10 Formulating the Design of HDASD SystemsDissolution and the bioavailability of a drug candidate are two areas that are unassessed through prevalent high-throughput screening. A hot-melt extrusion platform is one novel approach that is helping to manufacture a high drug-loaded, amorphous, solid dispersion system.Accelerating Processes 16 Innovations in Cell-Line DevelopmentHow pharma manufactures cells has evolved significantly; speed is of the essence, and by using techniques like continuous development, cell-line platforms can better support research timelines.18 Laboratory of the Future: Digitally Connected and AutomatedMachine learning, artificial intelligence, and robotics are supporting the development of better data gathering and interpretation, ensuring that the next generation of laboratories are ready to seamlessly glide into future innovations.24 Tools to TransformCybersecurity is an issue that faces companies large and small across pharma manufacturing, but hidden behind the veil of added security are improvements to a company’s efficiency, speed, and reliability.Microscopy SPOT LIGHT26 Rigorous Chemical Testing to Support and Enhance Every Step of the Drug Discovery PipelineWel-Screen’s experts in pharmaceutical technology and techniques deliver a wealth of analytics for detailing samples. Housing a range of services to support your science, including scanning electron microscopy and liquid chromatographymass spectroscopy, Wel-Sceen enhances your innovation.28 Correlative Raman Microscopy for Pharmaceutical Particle AnalysisIt may seem easy to take a new drug from its particulate form to the end user, however in between lies a range of analyses that need to be conducted to ensure quality. Of those analyses is Raman microscopy, one of the most versatile techniques available.Digital Health 32 The Coming of Age for Digital HealthThe COVID-19 pandemic has provided an array of opportunities for digital health to permeate the life science industry, and this has offered the chance for digital mental health to come to the fore through more personalised wearables and apps.34 Reorganisation Through Digital DetailingHow pharma companies function and operate between different roles can be the point of difference, and evolving the way this is organised across levels from healthcare professionals to the end customer can be vital.36 Stepping Up the Pace in Vaccine Development and ProductionThe route from vaccine development to rollout has always tended to be years, rather than months. Moving out of the COVID-19 pandemic, the pharma industry can now look forward to speeding this process for the next vaccine that’s needed.39 The Path to Smarter Digital HealthData and automation in synergy offer a wealth of benefits to those utilising them. CROs collecting heaps of data will soon become reliant on burgeoning artificial intelligence technologies that can sort and understand healthcare data at speed.42 1 Trillion Cells, 50 Million IndividualsFaced with a growing bank of data that shows no sign of halting, companies are choosing to place their faith in digital solutions. But, how can new software begin to compute the ever-increasing billions of cells that need to be categorised and validated?45 Virtual and Augmented Reality – Driving Data Insights in Life ScienceUnderstanding data and knowing what to do with those gained insights has always been an area of improvement for life science companies. With the introduction of virtual and augmented reality, the sector can develop new ways of seeing and analysing data.Genomics 48 Breaking Away From DNA BreaksBase and prime editing have followed one another into the genetic engineering world to provide an alternative to previous DNA technology. What does the future hold for these methods, and what can the industry expect from novel genome editors?52 Precision & Putamen: Optimising Paediatric Gene TherapyNeurological diseases, especially those involving paediatric patients, are of vital interest to biotechnology companies, with researchers delving into how genomics can provide a springboard for new and exciting treatment options.Features SPOT LIGHT10 Real-Time Monitoring of HPLC Pump PerformanceA new liquid flowmeter that introduces deeper analysis and more reliable parameters for HPLC separation results is now available and ready to support developers and manufacturers worldwide.54 ATMPs in the EU: Overcoming Regulatory HurdlesOver the last decade, 13 advanced therapy medicinal products were approved by the EMA, the attention now turns to how these vital medicines can be moved through the regulatory barriers in their way, and what can be done to help speed up the process.Regulars 50 EventsDive into the next quarter of events in the biotechnology and pharmaceutical industry stretching from California in the US to Essen, Germany, with a host of hybrid events to enjoy until the next IPT. Index of AdvertisersIFC.GEA 5. Thermo Fisher Scientific 9.Biopharma Group23. BMG Labtech 51.CPhI WorldwideIBC.ICONOBC.Natoli Engineering Company Inc. EXECUTIVE DIRECTOR PMGroup Worldwide Ltd Karl Equi
Innovations in Pharmaceutical Technology (ISSN: 1471-7204, USPS No: 025082) is published four times a year – March, June, September, and December – by Samedan Ltd.
The opinions and views expressed by the authors in this book are not necessarily those of the Editor the Publisher and, while every care has been taken in the preparation of the book, the Editor and the Publisher are not responsible for such opinions and views or for any inaccuracies in the articles.
The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred.
The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form, by any means – electronic, mechanical, photocopying, or otherwise – without the prior permission of the Publisher.